Costly tests may not help detect bladder cancer recurrence, study finds

March 3, 2010

In a new study from The University of Texas M. D. Anderson Cancer Center, researchers found that cystoscopy, the standard for screening for recurrence of early-stage bladder cancer, is a cost-effective method of detecting tumors.

Adding other tests to cystoscopy increases the cost, as well as the number of false positives that may result in emotional distress and unnecessary procedures, the investigators include.

The study was presented today in advance of the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium. Jose Karam, M.D., a fellow in M. D. Anderson's Department Genitourinary Oncology, presented the findings.

"Our research potentially will enable clinicians to make judicious use of the available ancillary 'urinary markers,' which would translate into costs savings plus less anxiety for patients," said Ashish Kamat, M.D., associate professor of Urology and director of M. D. Anderson's Urologic Oncology Fellowship Program.

"The tests frequently added to cystoscopy have many more false positives than commonly believed, and they can lead to unnecessary work-ups. Our findings also may help reduce the cost of caring for bladder cancer patients, which currently in is the range of $4 billion annually," continued Kamat, the study's senior author.

Early-stage bladder cancer, or non-muscle (NMIBC), has a high rate of recurrence. Patients are tested every three to six months, often for the rest of their lives, with the goal of catching the cancer early if it returns.

Cystoscopy is an outpatient procedure in which a tiny tube with a small camera attached is inserted through the urethra into the bladder. Doctors then are able to visually examine the inside of the bladder for tumors. Many times, in efforts to ensure accuracy and early detection of bladder , other tests are added to cystoscopy.

"In this study, we wanted to identify which bladder surveillance method provides acceptable rate while minimizing costs," said Karam.

Kamat and his colleagues prospectively evaluated 200 M. D. Anderson patients with NMIBC. They compared the accuracy and cost of cystoscopy alone and cystoscopy combined with:

  • Cytology, examining bladder cells with a microscope
  • NMP22, a urine test that tests the level of NMP22 protein
  • FISH (fluorescence in situ hybridization), a urine test for chromosomal aberrations in bladder cells
  • NMP22 confirmed by FISH
By looking at the number of tumors detected and the cost of the tests (based on Medicare 2009 data) plus the cost of work-up for a false positive result, researchers arrived at a cost per tumor detected for each method. Cystoscopy alone was the least expensive at $7,692, while cystoscopy plus FISH was the priciest at $19,111.

But despite their added costs, additional tests did not give better results. Cystoscopy was most cost effective in finding tumors. Cystoscopy had two false positives, the fewest of any test, while cystoscopy plus FISH had the most false positives at 30.

"There are some who believe that the ancillary tests have the property to predict recurrences early," Kamat said. "In order to account for this, we took into account tumors detected later - at the first follow-up - to assess whether the tests added to detection rates. Our results suggest that, while the ancillary tests did turn positive prior to actual tumor recurrence in a handful of patients, the vast majority were still falsely positive."

Kamat said he would like to see the findings of this study confirmed in the near future by a multi-center co-operative study.

Related Stories

Recommended for you

Team identifies a switch that may help target dormant cancer cells

September 26, 2017
A study by scientists at the University of Arizona and the University of Pittsburgh may hold the key to targeting dormant—or inactive —cancer cells, which are resistant to chemotherapy and other treatments. The results ...

Researchers discover how enzyme 'shape-shifts' in drug-resistant leukemia

September 26, 2017
St. Jude Children's Research Hospital structural biologists have deciphered how the structure of the enzyme called Abl regulates its activity, enabling the enzyme to switch itself on and off. Understanding Abl's regulation ...

Researchers identify gene variants linked to a high-risk children's cancer

September 25, 2017
Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery may assist doctors in better diagnosing ...

Prostaglandin E1 inhibits leukemia stem cells

September 25, 2017
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.

MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer

September 25, 2017
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing ...

Cancer vaccines need to target T cells that can persist in the long fight against cancer

September 25, 2017
Cancer vaccines may need to better target T cells that can hold up to the long fight against cancer, scientists report.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

phlipper
1 / 5 (1) Mar 03, 2010
Does't matter. If the doctor doesn't use the costly test and the patient and the patient's cancer is missed, he will get sued. It's not about good medicine, it's about protection againt law suits.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.